Complementary yet distinct roles for oestrogen receptor-α and oestrogen receptor-β in mouse mammary epithelial proliferation by Clarke, Robert B
135
BAG = ERβ agonist; BrdU = bromodeoxyuridine; E2 = oestradiol; ER = oestrogen receptor; KO = knock-out; PR = progesterone receptor; TAM =
tamoxifen.
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Introduction
There is strong evidence that the alpha form of the
oestrogen receptor (ERα) mediates the effects of
oestradiol (E2) on proliferation of mammary epithelial cells
although, paradoxically, it is rarely expressed in pro-
liferating cells [1,2]. In contrast, mammary glands of mice
in which the ERβ gene has been deleted develop
normally. However, the role of this ER isoform in
controlling growth and/or differentiation of the mammary
epithelium has yet to be defined. A recent paper by Cheng
and colleagues [3] examines the effects of E2, the
selective oestrogen receptor modulator tamoxifen (TAM),
and a novel ERβ-specific agonist, BAG, on proliferation
and steroid receptor expression in the mammary glands of
wild type mice and in those in which the ERβ gene has
been knocked out (KO).
Steroid receptors and cell proliferation
Ovariectomised mice were used to examine the
proliferative effects for 48 hours following treatment with
E2, TAM or BAG. The halogenated thymidine analogue
bromodeoxyuridine (BrdU) was used to label cells in
S-phase 0 and 24 hours into the treatment and tissues
were collected at 48 hours. This permitted the number of
proliferative mammary epithelial cells that accumulated over
the 48-hour treatment period to be examined. Surprisingly,
all three compounds induced similar numbers of BrdU-
labelled cells suggesting that TAM acts as an agonist on
the mammary glands of ovariectomised mice and that BAG
can elicit proliferation via ERβ. The authors concluded that
both ERα and ERβ can mediate the proliferative effects of
E2 on the mouse mammary epithelium.
Over the same time period, and also in mice treated
continuously for 3 weeks, the effect of E2 and TAM on
steroid receptor expression was examined using immuno-
histochemistry and Western blotting. ERα was clearly
shown to be down-regulated by E2 in both wild type and
ERβ KO animals, but little effect on ERβ or the E2-
regulated gene, progesterone receptor (PR), expression
could be demonstrated. Interestingly, TAM differed from
E2 in that it had little effect on ERα expression, but
reduced ERβ expression by about half. Over the 48 hours
following injection of E2, the cell cycle-associated protein
cyclin D1 accumulated and then disappeared from cell
nuclei with similar kinetics to the loss and re-expression of
ERα.
These latter data provided the rationale for a re-
examination of the relationship between proliferating cells
and ERα or PR expression. When BrdU-labelling was
carried out shortly before removing and processing the
tissue for immunohistochemistry, no association between
expression of either ERα or PR and BrdU uptake could be
demonstrated. However, when labelling was carried out
2 days prior to analysis, about 20% of BrdU-positive cells
were PR-positive. This result suggests that these dually
labelled cells are daughter cells of those that have
proliferated.
Previous studies that have generated similar data
conclude that proliferating cells respond to E2 indirectly
via paracrine or juxtacrine signalling [1,2]. However, in this
paper, the conclusion is that ERα is down-regulated in
proliferating cells in response to E2. If this is the case,
then an association between ERα and proliferating cells
should be demonstrable in the TAM-treated samples
where proliferation is increased but ERα is not down-
regulated. Secondly, since ERα and PR are known to be
co-expressed [1] but there is no downregulation of PR,
large numbers of BrdU-positive, PR-positive cells should
be detected. This is not the case.
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Conclusion
The article provides important new insights into E2-
induced proliferation mediated by both ERα and -β.
However, the conclusion that ERα is expressed and then
down-regulated in proliferating cells is not supported by
the data presented here.
The most interesting result is that proliferation of mammary
epithelial cells can be increased by the novel ERβ-specific
agonist BAG, suggesting that ERβ does, indeed, play a
role in mediating the effects of E2. They also show for the
first time in vivo that ERα is rapidly lost from the nucleus
following E2 and that ERβ is up-regulated by E2, but
down-regulated by TAM.
Other findings confirm the work of other groups and
demonstrate that: ERα is epithelial whereas ERβ is both
epithelial and stromal [4]; steroid receptor expression and
proliferation are dissociated but daughter cells express
receptors [5,6]; and ERβ is expressed by some proliferating
cells [7].
Rather than indicating a direct role for ERα and PR in
proliferating cells, the finding that daughter cells express
these steroid receptors suggests existence of a distinct
lineage that may act as a sensor cell population and
mediate the proliferative effects of E2 and/or progesterone
in the mammary gland.
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